Moving sum of number of positive patient result as a quality control tool

Jiakai Liu, Chin Hon Tan, Tony Badrick, Tze Ping Loh

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Recently, the total prostate-specific antigen (PSA) assay used in a laboratory had a positive bias of 0.03 μg/L, which went undetected. Consequently, a number of post-prostatectomy patients with previously undetectable PSA concentrations (defined as <0.03 μg/L in that laboratory) were being reported as having detectable PSA, which suggested poorer prognosis according to clinical guidelines. Through numerical simulations, we explored (1) how a small bias may evade the detection of routine quality control (QC) procedures with specific reference to the concentration of the QC material, (2) whether the use of 'average of normals' approach may detect such a small bias, and (3) describe the use of moving sum of number of patient results with detectable PSA as an adjunct QC procedure. The lowest QC level (0.86 μg/L) available from a commercial kit had poor probability (<10%) of a bias of 0.03 μg/L regardless of QC rule (i.e. 1:2S, 2:2S, 1:3S, 4:1S) used. The average number of patient results affected before error detection (ANPed) was high when using the average of normals approach due to the relatively wide control limits. By contrast, the ANPed was significantly lower for the moving sum of number of patient results with a detectable PSA approach. Laboratory practitioners should ensure their QC strategy can detect small but critical bias, and may require supplementation of ultra-low QC levels that are not covered by commercial kits with in-house preparations. The use of moving sum of number of patient results with a detectable result is a helpful adjunct QC tool.

Original languageEnglish
Pages (from-to)1709-1714
Number of pages6
JournalClinical Chemistry and Laboratory Medicine
Volume55
Issue number11
DOIs
Publication statusPublished - 26 Oct 2017

Fingerprint

Quality Control
Quality control
Prostate-Specific Antigen
Error detection
Prostatectomy
Assays
Guidelines
Computer simulation

Cite this

Liu, Jiakai ; Tan, Chin Hon ; Badrick, Tony ; Loh, Tze Ping. / Moving sum of number of positive patient result as a quality control tool. In: Clinical Chemistry and Laboratory Medicine. 2017 ; Vol. 55, No. 11. pp. 1709-1714.
@article{53ed49bc38024214b643c76830ae24d1,
title = "Moving sum of number of positive patient result as a quality control tool",
abstract = "Recently, the total prostate-specific antigen (PSA) assay used in a laboratory had a positive bias of 0.03 μg/L, which went undetected. Consequently, a number of post-prostatectomy patients with previously undetectable PSA concentrations (defined as <0.03 μg/L in that laboratory) were being reported as having detectable PSA, which suggested poorer prognosis according to clinical guidelines. Through numerical simulations, we explored (1) how a small bias may evade the detection of routine quality control (QC) procedures with specific reference to the concentration of the QC material, (2) whether the use of 'average of normals' approach may detect such a small bias, and (3) describe the use of moving sum of number of patient results with detectable PSA as an adjunct QC procedure. The lowest QC level (0.86 μg/L) available from a commercial kit had poor probability (<10{\%}) of a bias of 0.03 μg/L regardless of QC rule (i.e. 1:2S, 2:2S, 1:3S, 4:1S) used. The average number of patient results affected before error detection (ANPed) was high when using the average of normals approach due to the relatively wide control limits. By contrast, the ANPed was significantly lower for the moving sum of number of patient results with a detectable PSA approach. Laboratory practitioners should ensure their QC strategy can detect small but critical bias, and may require supplementation of ultra-low QC levels that are not covered by commercial kits with in-house preparations. The use of moving sum of number of patient results with a detectable result is a helpful adjunct QC tool.",
author = "Jiakai Liu and Tan, {Chin Hon} and Tony Badrick and Loh, {Tze Ping}",
year = "2017",
month = "10",
day = "26",
doi = "10.1515/cclm-2016-0950",
language = "English",
volume = "55",
pages = "1709--1714",
journal = "European Journal of Clinical Chemistry and Clinical Biochemistry",
issn = "1434-6621",
publisher = "WALTER DE GRUYTER & CO",
number = "11",

}

Moving sum of number of positive patient result as a quality control tool. / Liu, Jiakai; Tan, Chin Hon; Badrick, Tony; Loh, Tze Ping.

In: Clinical Chemistry and Laboratory Medicine, Vol. 55, No. 11, 26.10.2017, p. 1709-1714.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Moving sum of number of positive patient result as a quality control tool

AU - Liu, Jiakai

AU - Tan, Chin Hon

AU - Badrick, Tony

AU - Loh, Tze Ping

PY - 2017/10/26

Y1 - 2017/10/26

N2 - Recently, the total prostate-specific antigen (PSA) assay used in a laboratory had a positive bias of 0.03 μg/L, which went undetected. Consequently, a number of post-prostatectomy patients with previously undetectable PSA concentrations (defined as <0.03 μg/L in that laboratory) were being reported as having detectable PSA, which suggested poorer prognosis according to clinical guidelines. Through numerical simulations, we explored (1) how a small bias may evade the detection of routine quality control (QC) procedures with specific reference to the concentration of the QC material, (2) whether the use of 'average of normals' approach may detect such a small bias, and (3) describe the use of moving sum of number of patient results with detectable PSA as an adjunct QC procedure. The lowest QC level (0.86 μg/L) available from a commercial kit had poor probability (<10%) of a bias of 0.03 μg/L regardless of QC rule (i.e. 1:2S, 2:2S, 1:3S, 4:1S) used. The average number of patient results affected before error detection (ANPed) was high when using the average of normals approach due to the relatively wide control limits. By contrast, the ANPed was significantly lower for the moving sum of number of patient results with a detectable PSA approach. Laboratory practitioners should ensure their QC strategy can detect small but critical bias, and may require supplementation of ultra-low QC levels that are not covered by commercial kits with in-house preparations. The use of moving sum of number of patient results with a detectable result is a helpful adjunct QC tool.

AB - Recently, the total prostate-specific antigen (PSA) assay used in a laboratory had a positive bias of 0.03 μg/L, which went undetected. Consequently, a number of post-prostatectomy patients with previously undetectable PSA concentrations (defined as <0.03 μg/L in that laboratory) were being reported as having detectable PSA, which suggested poorer prognosis according to clinical guidelines. Through numerical simulations, we explored (1) how a small bias may evade the detection of routine quality control (QC) procedures with specific reference to the concentration of the QC material, (2) whether the use of 'average of normals' approach may detect such a small bias, and (3) describe the use of moving sum of number of patient results with detectable PSA as an adjunct QC procedure. The lowest QC level (0.86 μg/L) available from a commercial kit had poor probability (<10%) of a bias of 0.03 μg/L regardless of QC rule (i.e. 1:2S, 2:2S, 1:3S, 4:1S) used. The average number of patient results affected before error detection (ANPed) was high when using the average of normals approach due to the relatively wide control limits. By contrast, the ANPed was significantly lower for the moving sum of number of patient results with a detectable PSA approach. Laboratory practitioners should ensure their QC strategy can detect small but critical bias, and may require supplementation of ultra-low QC levels that are not covered by commercial kits with in-house preparations. The use of moving sum of number of patient results with a detectable result is a helpful adjunct QC tool.

UR - http://www.scopus.com/inward/record.url?scp=85031006070&partnerID=8YFLogxK

U2 - 10.1515/cclm-2016-0950

DO - 10.1515/cclm-2016-0950

M3 - Article

VL - 55

SP - 1709

EP - 1714

JO - European Journal of Clinical Chemistry and Clinical Biochemistry

JF - European Journal of Clinical Chemistry and Clinical Biochemistry

SN - 1434-6621

IS - 11

ER -